Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Mabs|April 7, 2020
Predicting Antibody Developability Profiles Through Early Stage Discovery ScreeningMarc Bailly, Carl Mieczkowski, Veronica Juan, et al.Frontiers in Immunology|May 23, 2022
Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization CapacityKalyan Pande, Scott A Hollingsworth, Miranda Sam, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2017
In Vivo Imaging of the Programmed Death Ligand 1 by 18F PETDinko E González Trotter, Xiangjun Meng, Paul McQuade, et al.Communications Biology|July 30, 2021
Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of actionRachel L Palte, Veronica Juan, Yacob Gomez-Llorente, et al.Mabs|May 10, 2025
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screeningKevin James Metcalf, Galen Wo, Jan Paulo Zaragoza, et al.Journal for Immunotherapy of Cancer|August 19, 2025
Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapyThierry O Fischmann, Daniel Malashock, Eunseon Ahn, et al.Molecular Cancer Therapeutics|April 2, 2020
Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody PembrolizumabBeth Hutchins, Gary C Starling, Mark A McCoy, et al.Journal of Medicinal Chemistry|April 30, 2026
Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug ConjugatesRyan V Quiroz, Simon B Lang, Rebecca E Johnson, et al.Journal of Medicinal Chemistry|April 30, 2026
Discovery of Novel N-Linked Camptothecin Linker-Payloads to Access Antibody-Drug Conjugates with High Target-Mediated In Vivo EfficacyVlad Bacauanu, Si-Jie Chen, Simon B Lang, et al.Journal for Immunotherapy of Cancer|September 13, 2022
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapyLars Guelen, Thierry O Fischmann, Jerelyn Wong, et al.Pageof 4